NCT01885689 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 52
- units
- Participants
- groups
- description
- CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure. clofarabine: Given IV melphalan: Given IV allogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant tacrolimus: Given IV or PO sirolimus: Given PO Pharmacological Study: Correlative studies
- id
- BG000
- title
- Treatment (Clofarabine, Melphalan, Transplant)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 42
- upper Limit
- 71
- value
- 62
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 27
- title
- Female
- measurements
- group Id
- BG000
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 42
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 52
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 52
- units
- Participants
- groups
- description
- CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4. TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0. GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure. clofarabine: Given IV melphalan: Given IV allogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant tacrolimus: Given IV or PO sirolimus: Given PO Pharmacological Study: Correlative studies
- id
- BG000
- title
- Treatment (Clofarabine, Melphalan, Transplant)
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 42
- upper Limit
- 71
- value
- 62
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 27
- title
- Female
- measurements
- group Id
- BG000
- value
- 25
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 42
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 52
- title
- United States
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle